Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.59 |
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.51 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708120 | 0.87 | MCHR1 (0.76) | MCHR1CHRM1HTR2ACYP2D6HRH3 | |
| SCHEMBL6226959 | 0.85 | MCHR1 (0.56) | MCHR1CHRM1HTR2ACYP2D6HRH3 | |
| SCHEMBL6705888 | 0.84 | MCHR1 (0.68) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL6708249 | 0.84 | MCHR1 (0.71) | MCHR1CHRM1HTR2ACYP2D6HRH3 | |
| SCHEMBL6705780 | 0.82 | MCHR1 (0.66) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL3110783 | 0.82 | RCE1 (0.55) | RCE1C5AR1LPAR1LPAR5 | |
| SCHEMBL6708011 | 0.80 | MCHR1 (0.60) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL708343 | 0.78 | LPAR1 (0.75) | RCE1C5AR1LPAR1LPAR5 | |
| SCHEMBL3126416 | 0.76 | LPAR1 (0.57) | RCE1C5AR1LPAR1LPAR5 | |
| SCHEMBL3868700 | 0.76 | MCHR1 (0.65) | MCHR1CHRM1HTR2ACYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1467996-A1 | PYRIMIDOTRIAZINES AS PHOSPHATASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003055883-A1 | PYRIMIDOTRIAZINES AS PHOSPHATASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | MCHR1 2/4885CHRM1 295/4885HTR2A 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.